Literature DB >> 17671966

Gene-based SNP mapping of a psychotic bipolar affective disorder linkage region on 22q12.3: association with HMG2L1 and TOM1.

James B Potash1, Silvia Buervenich, Nancy J Cox, Peter P Zandi, Nirmala Akula, Jo Steele, Jennifer A Rathe, Dimitrios Avramopoulos, Sevilla D Detera-Wadleigh, Elliot S Gershon, J Raymond DePaulo, Andrew P Feinberg, Francis J McMahon.   

Abstract

Genetic linkage studies in both bipolar affective disorder (BPAD) and schizophrenia have implicated overlapping regions of chromosome 22q. We previously reported that BPAD pedigrees containing multiple members with psychotic symptoms showed suggestive linkage to chromosome 22q12.3. Now we have tested 189 single nucleotide polymorphisms (SNPs) spanning a 3 Mb region around the linkage peak for association with BPAD in 305 families, unrelated cases, and controls. SNPs were selected in or near genes, resulting in coverage at a density of 1 SNP per 6.7 kb across the 22 annotated genes in the region. The strongest signal emerged from family-based association analysis of an 11-SNP, 54 kb haplotype straddling the gene HMG2L1 and part of TOM1. A 3-marker haplotype of SNPs within TOM1 was associated with BPAD (allele-wise P = 0.0011) and with psychotic BPAD (allele-wise P = 0.00049). As hypothesized, the mean odds ratio for the risk alleles across the region was 1.39 in the psychotic but only 0.96 in the non-psychotic subset. Genotype-wise analyses yielded similar results, but the psychotic/non-psychotic distinction was more pronounced with mean odds ratios of 1.91 versus 0.8. Permutation of genotype-wise results for rs2413338 in HMG2L1 showed an empirical P = 0.037 for the difference between subsets. HMG2L1 is a negative regulator of Wnt signaling, a pathway of interest in psychotic BPAD as it is activated by both mood stabilizer and anti-psychotic medications. Further work is needed to confirm these results and uncover the functional variation underlying the association signal. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17671966     DOI: 10.1002/ajmg.b.30574

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  8 in total

Review 1.  Genetics of bipolar disorder.

Authors:  Jordan W Smoller; Erica Gardner-Schuster
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 5.285

Review 2.  Synapsin III: role in neuronal plasticity and disease.

Authors:  Barbara Porton; William C Wetsel; Hung-Teh Kao
Journal:  Semin Cell Dev Biol       Date:  2011-07-30       Impact factor: 7.727

Review 3.  Neurodevelopmental Perspectives on Wnt Signaling in Psychiatry.

Authors:  Kimberly A Mulligan; Benjamin N R Cheyette
Journal:  Mol Neuropsychiatry       Date:  2017-01-13

4.  Repression of smooth muscle differentiation by a novel high mobility group box-containing protein, HMG2L1.

Authors:  Jiliang Zhou; Guoqing Hu; Xiaobo Wang
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

5.  Tom1l2 hypomorphic mice exhibit increased incidence of infections and tumors and abnormal immunologic response.

Authors:  Santhosh Girirajan; Paula M Hauck; Stephen Williams; Christopher N Vlangos; Barbara B Szomju; Sara Solaymani-Kohal; Philip D Mosier; Kimber L White; Kathleen McCoy; Sarah H Elsea
Journal:  Mamm Genome       Date:  2008-03-15       Impact factor: 2.957

Review 6.  The genetics of psychotic bipolar disorder.

Authors:  Fernando S Goes; Lia L O Sanders; James B Potash
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

7.  Association study of Wnt signaling pathway genes in bipolar disorder.

Authors:  Peter P Zandi; Pamela L Belmonte; Virginia L Willour; Fernando S Goes; Judith A Badner; Sylvia G Simpson; Elliot S Gershon; Francis J McMahon; J Raymond DePaulo; James B Potash
Journal:  Arch Gen Psychiatry       Date:  2008-07

Review 8.  Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action.

Authors:  Zachary Freyberg; Stephen J Ferrando; Jonathan A Javitch
Journal:  Am J Psychiatry       Date:  2009-11-16       Impact factor: 18.112

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.